Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals
Concentra Biosciences, LLC and its subsidiary entered into a merger agreement with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) for a cash acquisition price of $3.90 to $4.05 per share, plus a non-tradeable contingent value right (CVR). The tender offer to acquire outstanding shares expires on February 13, 2024. 16,604,692 shares have been tendered, representing 37.2% of outstanding shares. The acquisition is expected to close in February 2024.
The announcement of the merger agreement between Concentra Biosciences and Theseus Pharmaceuticals, including the tender offer details and the contingent value rights (CVR), is significant for the valuation and investment strategies concerning Theseus stock. The offer of $4.05 per share represents a premium over the market price prior to the announcement, which is a common practice to incentivize shareholder agreement. The CVR component is particularly noteworthy as it ties future payouts to the success of Theseus' programs, which could impact the long-term value proposition for investors. The high percentage of shares already tendered, along with the support agreements from stockholders representing 59% of the shares, suggests a strong likelihood of the merger's completion. This consolidation within the biopharmaceutical industry could lead to operational synergies and cost savings, potentially affecting Theseus' competitiveness and market share.
From a market perspective, the acquisition of Theseus by Concentra Biosciences may indicate a strategic move to enhance Concentra's product portfolio and market positioning. The CVR agreement suggests confidence in Theseus' pipeline and the potential for future revenue streams. However, it is also a risk-sharing mechanism, as it defers part of the compensation contingent upon future events. This acquisition could signal a trend in the pharmaceutical industry towards consolidation as companies seek to bolster their pipelines and reduce competition. The market's response to such mergers can be mixed, depending on the perceived benefits and the integration risks involved. Investors and stakeholders will be closely monitoring the actualization of the anticipated cost savings and the progress of Theseus' programs post-merger.
Legally, the structure of the merger agreement, with a tender offer followed by a merger, is a common approach in corporate acquisitions. It is designed to expedite the process of acquiring a controlling stake. The CVR is a legal instrument that provides additional rights to shareholders, often used in transactions with uncertain future outcomes. The use of CVRs can be complex and may lead to litigation if the conditions are not met or are disputed. The legal stipulation that shares not tendered will be converted into the right to receive the same cash and CVR consideration ensures that all shareholders are treated equitably. The reference to Delaware law for appraisal rights is also significant, as it provides a legal avenue for dissenting shareholders to potentially receive fair value for their shares if they do not agree with the terms of the transaction.
01/30/2024 - 08:00 AM
SAN DIEGO --(BUSINESS WIRE)--
As previously announced on December 22, 2023, Concentra Biosciences, LLC (“Parent”) and its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Purchaser”), entered into a merger agreement (the “Merger Agreement”) with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) (“Theseus”) whereby Purchaser will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") between $3.90 $4.05 $3.90 $0.15 80% of the net proceeds from any license or disposition of Theseus' programs effected within 180 days of closing of the merger and 50% of the potential aggregate value of certain specified potential cost savings realized within 180 days of the close of the merger, pursuant to a Contingent Value Rights Agreement. Pursuant to the Merger Agreement, on January 9, 2024, Purchaser and Parent commenced a tender offer to acquire all outstanding shares of Theseus common stock (the “Offer”).
Pursuant to the terms of the Merger Agreement, Parent, Purchaser and Theseus have determined that the Additional Price Per Share is the maximum of $0.15 $4.05
Pursuant to the terms of the Merger Agreement, Purchaser has extended the Offer’s expiration date so that the Offer and related withdrawal rights will expire at 6:00 p.m. Eastern Time on February 13, 2024, unless the expiration date is further extended in accordance with the terms of the Merger Agreement.
Stockholders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to the determination of the Additional Price Per Share or extension of the Offer expiration date. Broadridge Corporate Issuer Solutions, LLC, the depositary for the Offer, has advised Parent and Purchaser that, as of January 29, 2024, the last business day prior to the announcement of the extension of the Offer, 16,604,692 shares of Theseus’ common stock, representing approximately 37.2% of the outstanding shares of Theseus common stock, have been validly tendered pursuant to the Offer and not properly withdrawn. As previously announced, Theseus stockholders holding approximately 59% of Theseus common stock have signed support agreements to tender their shares in the Offer prior to the expiration date and support the merger.
The closing of the Offer is subject to certain conditions, including the tender of Theseus common stock representing at least a majority of the total number of outstanding shares, the availability of at least approximately $187.6 million Delaware law, will be converted into the right to receive the same Cash Amount and CVR consideration per share as is provided in the Offer. The acquisition is expected to close in February 2024.
Cautionary Notice Regarding Forward-Looking Statements
This communication contains “forward-looking statements” relating to the proposed acquisition of Theseus by Purchaser. Such forward-looking statements include, but are not limited to, the ability of Purchaser and Theseus to complete the transactions contemplated by the Merger Agreement, including the parties’ ability to satisfy the conditions to the consummation of the Offer contemplated thereby and the other conditions set forth in the Merger Agreement, statements about the expected timetable for completing the transactions, the potential effects of the acquisition on both Purchaser and Theseus, and the possibility that the conditions to payments under the CVRs will be met. In some cases, forward-looking statements are intended to be identified by terminology such as “believe,” “may,” “will,” “should,” “predict,” “goal,” “strategy,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect,” “seek” and similar expressions and variations thereof. Purchaser has based these forward-looking statements on current expectations and projections about future events, but there can be no guarantee that such expectations and projections will prove accurate in the future.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Actual results may differ materially from current expectations because of risks associated with uncertainties as to the timing of the Offer and the subsequent merger; uncertainties as to how many of Theseus’ stockholders unaffiliated with Purchaser will tender their shares in the Offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the merger and the Offer contemplated thereby may not be satisfied or waived; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; and the risk that stockholder litigation in connection with the Offer or the merger may result in significant costs of defense, indemnification and liability. Although Purchaser believes that the expectations reflected in such forward-looking statements are reasonable, it cannot guarantee future events, results, actions, levels of activity, performance or achievements, business and market conditions, the timing and results of any developments and whether the conditions to the closing of the proposed transaction are satisfied on the expected timetable or at all. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date they are made. Purchaser undertakes no obligation to publicly release any revisions to the forward-looking statements after the date hereof to conform these statements to actual results or revised expectations.
Additional Information and Where to Find It
This communication is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell shares of Theseus common stock or any other securities. This communication is also not a substitute for the Offer materials that Purchaser has filed with the SEC in connection with the Offer. On January 30, 2024, Purchaser filed with the SEC an amended Tender Offer Statement on Schedule TO-T (the “Amended Tender Offer Statement”) and Theseus filed with the SEC an amended Solicitation/Recommendation Statement on Schedule 14D-9 (the “Amended Solicitation/Recommendation Statement”).
THESEUS’ STOCKHOLDERS ARE URGED TO READ THE AMENDED TENDER OFFER STATEMENT MATERIALS (INCLUDING THE AMENDED OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE AMENDED SOLICITATION/RECOMMENDATION STATEMENT, BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE OFFER.
Theseus’ stockholders and other investors can obtain the Amended Tender Offer Statement, the Amended Solicitation/Recommendation Statement and other filed documents for free at the SEC’s website at www.sec.gov . Copies of the documents filed with the SEC by Theseus are available free of charge on the Investors page of Theseus’ website, www.theseusrx.com , or by contacting Theseus at ir@theseusrx.com . In addition, Theseus’ stockholders may obtain free copies of the Offer materials by contacting Morrow Sodali LLC, the information agent for the Offer. You may call Morrow Sodali LLC toll-free at (800) 662-5200 or email them at THRX@investor.morrowsodali.com . Banks and brokers may call collect at (203) 658-9400.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130962972/en/
inquiries@concentrabiosciences.com
Source: Concentra Biosciences, LLC
What is the ticker symbol for Theseus Pharmaceuticals, Inc.?
The ticker symbol for Theseus Pharmaceuticals, Inc. is THRX.
What is the cash acquisition price range per share for Theseus common stock?
The cash acquisition price per share for Theseus common stock is between $3.90 and $4.05.
What is the expiration date for the tender offer to acquire outstanding shares of Theseus common stock?
The expiration date for the tender offer is February 13, 2024.
How many shares have been tendered as of January 29, 2024?
As of January 29, 2024, 16,604,692 shares of Theseus' common stock have been tendered, representing approximately 37.2% of the outstanding shares.
When is the acquisition expected to close?
The acquisition is expected to close in February 2024.
